Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome

被引:108
作者
Wong, ND
Pio, JR
Franklin, SS
L'Italien, GJ
Kamath, TV
Williams, GR
机构
[1] Univ Calif Irvine, Heart Dis Prevent Program, Irvine, CA 92697 USA
[2] Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA
关键词
D O I
10.1016/S0002-9149(03)00392-8
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
We estimated the coronary heart disease (CHID) events that are preventable by treatment of lipids and blood pressure in patients with metabolic syndrome (MetS), a contributor to coronary heart disease (CHD). Among patients aged 30 to 74 years (without diabetes or CHD) in the United States, MetS was defined by National Cholesterol Education Program criteria. CHD events over a period of 10 years were estimated by Framingham algorithms. Events that could be prevented by statistically "controlling" blood pressure, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDC) cholesterol to either normal or optimal levels according to national guidelines were calculated. Of 7.5 million men and 9.0 million women aged 30 to 74 years with MetS, approximately 1.5 million men and 0.45 million women, if untreated, developed CHD events in 10 years. In men and women, blood pressure control to normal levels "prevented" 28.1% and 12.5% of CHD events, respectively (p <0.01); control to optimal levels resulted in preventing 28.2% and 45.2% of events, respectively (P <0.01). Control of HDL cholesterol to normal levels resulted in preventing 25.3% of events in men and 27.3% in women; optimal control prevented 51.2% and 50.6% of events, respectively. Control of LDL cholesterol to normal levels prevented 9.3% of events in men and 9.8% of events in women; control to optimal levels prevented 46.2% and 38.1% of events (p <0.05), respectively. Control of all 3 risk factors to normal levels resulted in preventing 51.3% of events for men and 42.6% tor women; control to optimal levels resulted in preventing 80.5% and, 82.1% of events, respectively. Thus, many CHD events in patients with MetS may be preventable by nominal or optimal control of lipids and/or blood pressure. (C) 2003 by Excerpta Medica, Inc.
引用
收藏
页码:1421 / 1426
页数:6
相关论文
共 9 条
[1]
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
[2]
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease [J].
Brown, BG ;
Zhao, XQ ;
Chait, A ;
Fisher, LD ;
Cheung, MC ;
Morse, JS ;
Dowdy, AA ;
Marino, EK ;
Bolson, EL ;
Alaupovic, P ;
Frohlich, J ;
Albers, JJ ;
Serafini, L ;
Huss-Frechette, E ;
Wang, S ;
DeAngelis, D ;
Dodek, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (22) :1583-1592
[3]
REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B [J].
BROWN, G ;
ALBERS, JJ ;
FISHER, LD ;
SCHAEFER, SM ;
LIN, JT ;
KAPLAN, C ;
ZHAO, XQ ;
BISSON, BD ;
FITZPATRICK, VF ;
DODGE, HT .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1289-1298
[4]
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[5]
Clinical significance of cardiovascular dysmetabolic syndrome [J].
Deedwania, PC .
CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2002, 3 (1)
[6]
Prevalence of the metabolic syndrome among US adults - Findings from the Third National Health and Nutrition Examination Survey [J].
Ford, ES ;
Giles, WH ;
Dietz, WH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (03) :356-359
[7]
Cardiovascular morbidity and mortality associated with the metabolic syndrome [J].
Isomaa, B ;
Almgren, P ;
Tuomi, T ;
Forsén, B ;
Lahti, K ;
Nissén, M ;
Taskinen, MR ;
Groop, L .
DIABETES CARE, 2001, 24 (04) :683-689
[8]
Prediction of coronary heart disease using risk factor categories [J].
Wilson, PWF ;
D'Agostino, RB ;
Levy, D ;
Belanger, AM ;
Silbershatz, H ;
Kannel, WB .
CIRCULATION, 1998, 97 (18) :1837-1847
[9]
1995, 3 NUTR MONITORING US, V1